312 related articles for article (PubMed ID: 33002195)
1. Neoadjuvant immunotherapy for melanoma.
Lee AY; Brady MS
J Surg Oncol; 2021 Mar; 123(3):782-788. PubMed ID: 33002195
[TBL] [Abstract][Full Text] [Related]
2. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.
Long GV; Menzies AM; Scolyer RA
J Clin Oncol; 2023 Jun; 41(17):3236-3248. PubMed ID: 37104746
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Pelster MS; Amaria RN
Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant immunotherapy for melanoma.
Thomas D; Bello DM
J Surg Oncol; 2021 Mar; 123(3):789-797. PubMed ID: 33595889
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant immunotherapy in nonsmall cell lung cancer.
Pall G
Curr Opin Oncol; 2021 Jan; 33(1):59-63. PubMed ID: 33229874
[TBL] [Abstract][Full Text] [Related]
7. The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment.
O'Donnell JS; Hoefsmit EP; Smyth MJ; Blank CU; Teng MWL
Clin Cancer Res; 2019 Oct; 25(19):5743-5751. PubMed ID: 31040150
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting.
Herrscher H; Robert C
Curr Opin Oncol; 2020 Mar; 32(2):106-113. PubMed ID: 31876547
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Treatments for Advanced Resectable Melanoma.
Liu JY; Lowe M
J Surg Oncol; 2019 Jan; 119(2):216-221. PubMed ID: 30589079
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma.
Ferraresi V; Vari S
Hum Vaccin Immunother; 2022 May; 18(3):1971015. PubMed ID: 34882516
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma.
Spagnolo F; Croce E; Boutros A; Tanda E; Cecchi F; Mascherini M; Solari N; Cafiero F; Queirolo P
Expert Rev Anticancer Ther; 2020 May; 20(5):403-413. PubMed ID: 32326767
[No Abstract] [Full Text] [Related]
13. Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials.
Patel A; Skitzki J
J Surg Oncol; 2022 Jan; 125(1):38-45. PubMed ID: 34897704
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
Gutierrez-Sainz L; Cruz-Castellanos P; Higuera O; de Castro-CarpeƱo J
Curr Treat Options Oncol; 2021 Aug; 22(10):91. PubMed ID: 34424417
[TBL] [Abstract][Full Text] [Related]
15. Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma.
McKean MA; Amaria RN
Am J Clin Dermatol; 2018 Oct; 19(5):639-646. PubMed ID: 30039289
[TBL] [Abstract][Full Text] [Related]
16. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
[TBL] [Abstract][Full Text] [Related]
17. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.
Laino AS; Woods D; Vassallo M; Qian X; Tang H; Wind-Rotolo M; Weber J
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581042
[TBL] [Abstract][Full Text] [Related]
18. The potential of BRAF-targeted therapy combined with immunotherapy in melanoma.
Naderi-Azad S; Sullivan R
Expert Rev Anticancer Ther; 2020 Feb; 20(2):131-136. PubMed ID: 32003263
[No Abstract] [Full Text] [Related]
19. Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges.
Krishnamoorthy M; Lenehan JG; Maleki Vareki S
J Natl Cancer Inst; 2021 Jul; 113(7):823-832. PubMed ID: 33432320
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease.
Weber J; Glutsch V; Geissinger E; Haug L; Lock JF; Schneider F; Kneitz H; Goebeler M; Schilling B; Gesierich A
Br J Dermatol; 2020 Sep; 183(3):559-563. PubMed ID: 31773720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]